Based on its pro-tumor and anti-tumor functions, in humans, IL33 is correlated with poor prognosis in glioma and hepatocellular carcinoma (W. Wang, Wu, Ji, & Wu, 2020; J. Zhang, Wang, Ji, Ding, & Lu, 2017) while it is associated with better prognosis in lung cancer and colorectal cancer (O’Donnell et al., 2016; Yang et al., 2018). Here, IL33 is linked to neoplasm.